Skip to main content
Premium Trial:

Request an Annual Quote

Shares in Bruker, Stratagene Bounce Back

Shares in Bruker BioSciences and Stratagene continued their bumpy ride, bouncing back this week to post gains of 8.42 percent and 6.74 percent, respectively. Both firms' stocks had led decliners in the BCW Index last week, following a week of big gains.

Molecular Devices posted the largest decline for the week — 2.96 percent — giving back its gain of 2.69 percent during last week's tracking period.

Overall, the Index closed up .13 percent for the week ended Tuesday, while the Nasdaq rose .4 percent, the Nasdaq Biotech Index dropped 1.1 percent, and the Dow Jones Industrial Average fell .7 percent.

BioCommerce Week Index of Diversified Molecular Biology Tool Companies
Company
Ticker
Current Price
(Mar. 28, 2006)
Last Price
(Mar. 21, 2006)
% change
Agilent
A
36.27
37.12
-2.29
Applied Biosystems
ABI
27.52
27.13
1.44
Beckman
BEC
54.68
53.91
1.43
Bio-Rad
BIO
58.51
57.25
2.20
Bruker
BRKR
5.02
4.63
8.42
Fisher Scientific
FSH
68.81
68.55
0.38
GE
GE
33.6
34.34
-2.15
Harvard Bio
HBIO
4.33
4.27
1.41
Invitrogen
IVGN
70.72
71.29
-0.80
Molecular Devices
MDCC
31.49
32.45
-2.96
PerkinElmer
PKI
23.15
23.06
0.39
Qiagen
QGEN
14.63
14.7
-0.48
Sigma
SIAL
64.32
64.11
0.33
Stratagene
STGN
10.29
9.64
6.74
Thermo
TMO
36.12
35.58
1.52
Waters
WAT
42.79
43.47
-1.56
BCW Index Average
36.39
36.34
0.13
The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.